Drug Profile
DB 340
Latest Information Update: 02 Dec 2003
Price :
$50
*
At a glance
- Originator Georgia State University; Nonindustrial source
- Developer Georgia State University
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 02 Dec 2003 Discontinued - Preclinical for HIV-1 infections in USA (unspecified route)
- 21 May 2001 No-Development-Reported for HIV-1 infections in USA (Unknown route)
- 24 Apr 1998 Preclinical development for HIV-1 infections in USA (Unknown route)